Abstract 572: Pre-clinical evaluation of Claudin 18.2 TAC T cells for the treatment of gastric cancer
Authors: Tania Benatar, Ling Wang, Thanyashanthi Nitya-Nootan, Heather MacGregor, Suzanna Prosser, Philbert Ip, Prabha Lal, Laura Shaver, Sadhak Sengupta, Christopher W. Helsen, Andreas G. Bader
Journal: Cancer Research (2022)

Background: The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the re-direction of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex with the goal to elicit a safe and durable anti-tumor response. Based on this preclinical pharmacology and toxicology data, TAC01-HER2, a first-in-class TAC T product targeting HER2 (ERBB2), has entered a phase I/II clinical trial in patients with HER2-positive solid tumors. Here, we present the development of a new TAC T product targeting Claudin 18.2 (CLDN18.2) to treat gastric cancer. CLDN18.2 belongs to a family of Claudin tight junction proteins whose expression is naturally exclusive to normal stomach. In gastric cancer cells, however, CLDN18.2 surface expression is upregulated and perturbed, leading to tumor-selective surface expression of CLDN18.2. Thus, CLDN18.2 is a preferred antigen for the specific targeting of tumor cells via TAC T cells.Materials and Methods: CLDN18.2-TAC receptor functionality was characterized using a variety of in vitro and in vivo assays. In vitro assays were based on flow cytometric analysis of TAC surface staining and cytokine release. Cytotoxicity was assessed via luminescence-based co-culture assays and real-time microscopy. In vivo studies examined the anti-tumor effect of TAC-engineered T-cells against established solid CLDN18.2 expressing tumor xenografts.Results: The CLDN18.2-TAC receptor showed strong surface expression and specific activation when co-cultured with a variety of cancer cells expressing CLDN18.2 in vitro. Secretion of IL2, IFNg and TNFa were comparable with cytokine levels produced by activated control TAC T cells. In vitro cytotoxicity assays demonstrated a strong anti-CLDN18.2 response and killing of CLDN18.2 expressing target cell lines. No increases in cytokine levels and no cytotoxicity were observed in non-transduced T cells and CLDN18.2-TAC T cells co-cultured with CLDN18.2-negative target cells, indicating that the T cell response is specific to the CLDN18.2 antigen. Intravenous administration of CLDN18.2-TAC T cells in mice carrying CLDN18.2-positive solid tumor xenografts led to a sustained anti-tumor response.Conclusion: The in vitro and in vivo data confirm strong and specific activity of CLDN18.2-targeted TAC T cells against CLDN18.2-expressing solid tumor models and highlight the versatility of the TAC platform for therapeutic applications in solid tumors.Citation Format: Tania Benatar, Ling Wang, Thanyashanthi Nitya-Nootan, Heather MacGregor, Suzanna Prosser, Philbert Ip, Prabha Lal, Laura Shaver, Sadhak Sengupta, Christopher W. Helsen, Andreas G. Bader. Pre-clinical evaluation of Claudin 18.2 TAC T cells for the treatment of gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 572.